The case for & against
Bull & Bear analysis
AbbVie Inc. (NYSE: ABBV) is a global biopharmaceutical company that has established a strong foothold in various therapeutic areas such as immunology, oncology, neuroscience, and aesthetics. Known for its robust R&D pipeline, AbbVie is particularly recognized for its flagship products Skyrizi and Renvoke, which are leading the charge in the competitive immunology space. The company is also poised for growth in neuroscience with products targeting conditions like Parkinson's disease, and maintains a presence in aesthetics through its established brands like Botox. AbbVie’s ongoing commitment to innovation through acquisitions and internal development positions it strategically within the evolving biopharmaceutical landscape.
Bull says
- ↑Q2 2026 net revenues of $17B (+10.2% YoY) fueled by Skyrizi and Renvoke.
- ↑Adjusted EPS of $3.65 beat guidance; full-year revenue guide raised to $67.6B.
- ↑Skyrizi market share drives projected $21.7B in immunology sales for 2026.
- ↑Pipeline spans ~90 clinical programs; RINVOC approval could yield $2B peak sales.
- ↑Plans $10B U.S. manufacturing investment over next decade to boost capacity.
- ↑Apogee acquisition enhances R&D capabilities and pipeline growth potential.
Bear says
- ↓Humira revenues set to decline over $4B in 2026 due to biosimilars.
- ↓Aesthetics segment sales fell 4.2% as consumer spending remains weak.
- ↓IRA-driven pricing headwinds impose low single-digit revenue pressures across products.
- ↓Short interest remains elevated, signaling growing trader skepticism.
- ↓Negative analyst revisions and low institutional ownership limit upside momentum.
- ↓Low earnings yield and profitability pressures could undermine shareholder returns.
Investment themes with ABBV
Companies paying above-average dividends
Genetic and drug innovations driving medical breakthroughs
Services and products for aging population
Earnings Call · Q2 2025 · Mgmt. Guidance
Transcript signals
Bull points
- I think we'll be able to work through it. We still see high levels of interest in aesthetic procedures, and we do see
- I also did highlight that I do think something's different in terms of the sentiment around this natural look and worry about being overfilled in terms of the derma fillers. All of these are addressable. And I also think that we have the right portfolio, and we also have the right disruptive innovations that's pretty close, particularly around the toxin space with our short-acting fast-on, fast-off trentenobot E. So I do think we're set up for taking advantage of the long-term recovery, and we'll look forward to that as we continue to progress the strategy.
- we would not expect VanClexa to be negotiated. And that's an example of a good policy change where innovation is being rewarded and not penalized.
Bear points
- longer-term impact on the pocketbook of the consumers has just been more chronic, and we've seen that across even just recent reports on luxury good items and significant issues. So I do think it's more chronic than we've seen before.
- We've had a prolonged economic headwind.
- net neutral